The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: A cohort study

Haematologica

Volumn 91, Issue 4, 2006, Pages 503-508

  Federici, Augusto B ^a   Santagostino, Elena ^a   Rumi, Maria Grazia ^a   Russo, Antonio ^b   Mancuso, Maria Elisa ^a   Soffredini, Roberta ^a   Mannucci, Pier M ^a   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Local Health Authority   (Italy)

Author keywords

Desmopressin; End stage liver disease; Hemophilia A and B; Hepatitis C virus; Plasma factor concentrates; Von willebrand's disease

Indexed keywords

AMINOTRANSFERASE;

ABDOMINAL RADIOGRAPHY; ADULT; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; INFECTION RISK; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; RISK FACTOR; ULTRASOUND; VON WILLEBRAND DISEASE;

ADULT; BLOOD TRANSFUSION; COHORT STUDIES; FEMALE; GENOTYPE; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS C; HUMANS; ITALY; MALE; PREVALENCE; TREATMENT OUTCOME; VON WILLEBRAND DISEASE;

EID: 33645961294     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Fletcher ML, Trowel JM, Craske J, Pavier K, Rizza CT. Non-A non B hepatitis after transfusion of factor VIII in infrequently treated patient Br Med J 1983;287:1754-7.
2. Kernoff PBA, Lee CA, Karayiannis P, Thomas HC. High risk of non-A non B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Br J Haematol 1985;60:469-79.
3. Rumi MG, Colombo M, Gringeri A, Mannucci PM. High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels. Ann Intern Med 1990;112:379-80
4. Mannucci PM, Colombo M. Virucidal treatment of clotting factor concentrates. Lancet 1988;332:782-5.
5. Mannucci PM, Schimpf K, Brettler DB, Ciavarella N, Colombo M, Lusher J, e al. Low risk for hepatitis C in hemophiliacs given a high-purity pasteurized factor VIII concentrate. The International Study Group. Ann Intern Med 1990;113:27-32.
6. UK Hemophilia Centre Directors Study group on surveillance of virus transmission by concentrates. Effects of dry-heating of coagulation factor concentrates at 80°C for 72 hours on transmission of non-A non-B hepatitis. Lancet 1988;332:814-6.
7. Horowitz MS, Rooks C, Horowitz B, Hilgartner MW. Virus safety of solvent/detergent-treated anti-haemophilic factor concentrate viral infection. Lancet 1988;2:186-9.
8. Danahue JG, Munoz DVM, Ness PM, Brown DE, Yawn DH, McAllister HA, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992;327:369-73.
9. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infection. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334:1685-90.
10. Legler TJ, Riggert J, Simpson G, Wolf C, Humpe A, Munzel U, et al. Testing of individual blood donation for HCV RNA reduces the residual risk of transfusion-transmitted HCV infection. Transfusion 2000;40:1192-7.
11. Colombo M, Mannucci PM, Brettler DB, Girolami A, Lian ECY, Rodeghiero F, et al. Hepatocellular carcinoma in hemophilia. Am J Hematol 1991;37:243-6.
12. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee CA. The progression of HCV-associated liver disease in a cohort of hemophilic patients. Br J Haematol 1994;87:555-61.
13. Darby SC, Ewart DW, Giangrande PLF, Spooner RJD, Rizza CR, Dusheiko GM, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given products contaminated with hepatitis C. Lancet 1997;350:1425-31.
14. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001;83:1112-5.
15. Goedert JJ, Eyster E, Lederman MM, et al. for the Multicenter Hemophilia Cohort Study. End stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002;100:1584-9.
16. Mannucci PM. Treatment of von Willebrand disease. N Engl J Med 2004;351:683-94.
17. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994;71:520-5.
18. Federici AB, Castaman G, Mannucci PM. Guidelines for the diagnosis and management of von Willebrand disease in Italy. The Italian Association of Hemophilia Centers. Haemophilia 2002; 8:607-21.
19. Bruix J, Sherman M, Llovet JM, Beaurgnad M, Lencioni R, Christensen F, et al. Clinical management on hepatocellular carcinoma. Conclusions of the Barcelona, 2000 EASL Conference. J Hepatol 2001;35:421-30.
20. Soffredini R, Rumi MG, Parravicini ML, Ronchi G, Del Ninno E, Russo A, et al. Serum levels of hepatitis C virus core antigen as a marker of infection and response to therapy. Am J Gastroenterol 2004;99:1738-43.
21. Saldanha J, Lelie N, Heath A. WHO Collaborative Study Group. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV-RNA. Vox Sang 1999;76:149-58.
22. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand's disease. Lancet 1977;1:869-72.
23. Rumi MG, Santagostino E, Morfini M, Gringeri A, Tagariello G, Chistolini A, et al. A multicenter controlled, randomized, open trial of interferon -2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis. The Hepatitis Study Group of the Association of Italian Hemophilia Centers. Blood 1997;89:3529-33.
24. Fujimura Y, Ishimoto S, Shimoyama T, Narita N, Kuza Y, Yoshioka A, et al. Genotype and multiple infections with hepatitis C virus in patients with haemophilia A in Japan. J Virol Hepatol 1996;3:79-84.
25. Guadagnino V, Stroffolini T, Rapicetta M, Costantino A, Kondili LA, Menniti-Ippolito F, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 1997;26:1006-11.
26. Nousbaum JB, Pol S, Nalpas B, Nalpas B, Landais P, Berthelot P, et al. Hepatitis C virus C 1b infection in France and Italy. The Collaborative Study Group. Ann Intern Med 1995;122:161-8.
27. Pistello M, Maggi F, Vatteroni L, Cecconi N, Panicucci F, Bresci GP, et al. Prevalence of hepatitis C virus genotypes in Italy. J Clin Microbiol 1994;32:232-4.
28. Di Marco V, Lo Iacono, Almasio P, et al. Long term efficacy of α-interferon in β-thalassemics with chronic hepatitis C. Blood 1997;90:2207-12.
29. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of β-thalassemia major in North America. The Thalassemia Clinical Research Network. Blood 2004;104:34-9.
30. Mannucci PM, Schimpf K, Abe T, Aledort LM, Anderle K, Brettler DB, et al. Low risk of viral Infection after administration of vapor-heated factor VIII concentrates. Transfusion 1992;32:134-8.
31. Kreuz W, Auerswald G, Bruckmann C, Zieger B, Linde R, Funk M, et al. Prevention of hepatitis C virus infection in children with haemophilia A and B and von Willebrand's disease. Thromb Haemost 1992;67:184.
32. Klarmann D, Kreuz W, Auerswald G, Auberger K, Rabenau H, Gurtler L, et al. Hepatitis C and pasteurised factor VIII and IX concentrates. Thromb Haemost 1995;73:736-7.
33. Benvegné L, Pontisso P, Cavalletto D, Noventa F, Chemello L, Alberti A. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997;25:211-5.
34. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. The International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32.
35. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. The PEGASYS International Study Group. Ann Intern Med 2004;140:346-55.
36. Mauser-Bunschoten EP, Bresters D, van Drimmelen AA, Roosendaal G, Cuypers HT, Reesink HW, et al. Hepatitis C infection and viremia in Dutch hemophilia patients J Med Virol 1995;45:241-6.
37. Eyster ME, Sanders J, Goedert JJ. Viral clearance occurs very early during the natural resolution of hepatitis C virus infection in persons with haemophilia. Haemophilia 2004;10:75-80
38. Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, et al Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurement of serum viral load. Hepatology 2003;37:60-4.
39. Zhang M, Rosenberg PS, Brown DL, Preiss L, Konkle BA, Eyster ME, et al. Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. Blood 2006;107:892-7.
40. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992;16:273-81.
41. Seeff LB, Miller RN, Rabkin CS, Buskell-Bales Z, Straley-Eason KD, Smoak BL, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105-11.
42. Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med 1993;119:110-5.
43. Thomas DL, Astemborski J, Rai RM, Amania FA, Schaeffer M, Galai N, Noltet al. The natural history of hepatitis C virus infection. Host, viral and environmental factors. JAMA 2000;284:450-6.
44. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002;36 Suppl 1:5152-60.
45. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmordue O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-40.
46. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002;36 Suppl 1:5121-7.
47. Santagostino E, Rumi MG, Rivi M, Colombo M, Mannucci PM. Sustained suppression of hepatitis C virus by interferon and ribavirin in hemophilic patients not responding to interferon monotherapy. The Hepatitis Study Group of the Association of Italian Hemophilia Centers. Blood 2002;99:1089-91.
48. Santagostino E, De Filippi F, Rumi MG, Rivi M, Colombo M, Mannucci PM. Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients. The Hepatitis Study Group of the Association of Italian Hemophilia Centers. Transfusion 2004;44:790-4.